3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Status
Active not recruiting
2
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Conditions
Carcinoma, Non-Small-Cell Lung
8
Uterine Cervical Neoplasms
4
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Advanced Solid Tumors
4
Lung Neoplasms
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Solid Tumor
2
Ovarian Neoplasms
2
Neoplasms
2
Melanoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Adenocarcinoma Of Esophagus
2
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Metastatic Urothelial Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Kidney Neoplasms
1
Erythrocytosis, Familial, 4
1
Endometrial Neoplasms
1
Carcinoma, Merkel Cell
1
Interventions
Carboplatin
98
Pemetrexed
70
pembrolizumab
68
Cisplatin
59
Paclitaxel
54
Docetaxel
45
Gemcitabine
37
Erlotinib Hydrochloride
24
Nivolumab
23
osimertinib
17
Bevacizumab
17
durvalumab
14
Cetuximab
13
130-nm albumin-bound paclitaxel
13
Gefitinib
11
Etoposide
11
Drug Therapy
11
Ipilimumab
9
Injections
9
Albumin-Bound Paclitaxel
9
Vinorelbine
8
Radiotherapy
8
motexafin gadolinium
7
capmatinib
7
atezolizumab
7
epacadostat
6
Taxes
6
Cyclophosphamide
6
vandetanib
5
entinostat
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lung Neoplasms
×
zimberelimab
×
Clear all
NCT04736173
2026-06-01
ARC-10
Arcus Biosciences, Inc.
Phase 2
Active not recruiting
169 enrolled
NCT05633667
2026-06-01
VELOCITY-Lung
Gilead Sciences
Phase 2
Active not recruiting
192 enrolled
NCT04262856
2025-08-26
ARC-7
Arcus Biosciences, Inc.
Phase 2
Completed
151 enrolled